Quote from Guest on May 14, 2022, 12:00 am
Quote from brad on May 5, 2022, 11:19 pm
We have a few of these and they tend me be really fast in budget negotiations with a couple exceptions. They seem to range from $1200-$1600/patient with one terrible company who wants to pay closer to $300/patient.
Great studies if you have the volume though.
These are all over the place, but be very wary when you take them. They seem like easy money, but then the payments are held hostage until ALL data are entered (this could take 6-9 months) AND some of the start-up companies tend to bait and switch the inclusion/exclusion so you think you'll enroll study arms that they close immediately. Higher phase cancers tend to take more work. Therefore either normalize your budget by the targeted patient population or stratify based on phase enrolled (not my preference here, it doesn't feel right to put a price tag on someone's terminal illness).
You also have to be very clear on the expected data entry. We had one sponsor come to us with a russian nest doll source document - The sponsors expected 7 pages of source PER polyp in a colorectal study. Thats a pandora's box of work and way too much for what they are paying.
I've gotten those low ball offers for $300/patient (generally "normals"), and we've had as high as 2,200/patient for the higher phase patients with tissue biopsies. We are averaging around 1500 per patient with OH, but again, be very careful with the hidden work.
In general - Just be careful. Use these studies as fillers, and be damn sure you communicate fully the expected data collection, any software package/portal used, and never agree to enrollment minimums without a substantial OH risk bump.
There is one advantage to these studies - Since they are one-and-dones, if the sponsor ticks you off, just... stop enrolling..... they change their mind really quick once they realize your value.
Quote from brad on May 5, 2022, 11:19 pm
We have a few of these and they tend me be really fast in budget negotiations with a couple exceptions. They seem to range from $1200-$1600/patient with one terrible company who wants to pay closer to $300/patient.
Great studies if you have the volume though.
These are all over the place, but be very wary when you take them. They seem like easy money, but then the payments are held hostage until ALL data are entered (this could take 6-9 months) AND some of the start-up companies tend to bait and switch the inclusion/exclusion so you think you'll enroll study arms that they close immediately. Higher phase cancers tend to take more work. Therefore either normalize your budget by the targeted patient population or stratify based on phase enrolled (not my preference here, it doesn't feel right to put a price tag on someone's terminal illness).
You also have to be very clear on the expected data entry. We had one sponsor come to us with a russian nest doll source document - The sponsors expected 7 pages of source PER polyp in a colorectal study. Thats a pandora's box of work and way too much for what they are paying.
I've gotten those low ball offers for $300/patient (generally "normals"), and we've had as high as 2,200/patient for the higher phase patients with tissue biopsies. We are averaging around 1500 per patient with OH, but again, be very careful with the hidden work.
In general - Just be careful. Use these studies as fillers, and be damn sure you communicate fully the expected data collection, any software package/portal used, and never agree to enrollment minimums without a substantial OH risk bump.
There is one advantage to these studies - Since they are one-and-dones, if the sponsor ticks you off, just... stop enrolling..... they change their mind really quick once they realize your value.
